Modality
Gene Editing
MOA
KRASG12Di
Target
BET
Pathway
JAK/STAT
CTCL
Development Pipeline
Preclinical
~May 2015
→ ~Aug 2016
Phase 1
~Nov 2016
→ ~Feb 2018
Phase 2
~May 2018
→ ~Aug 2019
Phase 3
Nov 2019
→ Nov 2029
Phase 3Current
NCT05981307
2,817 pts·CTCL
2024-09→2027-08·Active
NCT03557139
1,564 pts·CTCL
2019-11→2029-11·Active
4,381 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-08-171.4y awayPh3 Readout· CTCL
2029-11-193.6y awayPh3 Readout· CTCL
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P3
Active
P3
Active
Catalysts
Ph3 Readout
2027-08-17 · 1.4y away
CTCL
Ph3 Readout
2029-11-19 · 3.6y away
CTCL
Active|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05981307 | Phase 3 | CTCL | Active | 2817 | ACR20 |
| NCT03557139 | Phase 3 | CTCL | Active | 1564 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| RHH-1969 | Roche | Approved | BET | |
| NVS-5439 | Novartis | Preclinical | BET | |
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| Adagracapivasertib | BeiGene | NDA/BLA | BET | |
| 207-5197 | Samsung Biologics | Approved | BET |